| Ytd | -66.67% | |
| 1y | -60.81% |
| Open | 3.75 | Prev Close | 3.75 | Low | 3.72 | High | 3.79 | Mkt Cap | 287.64M |
| Vol | 1.80M | Avg Vol | 1.54M | EPS | -1.21 | P/E | N/A | Forward P/E | -3.84 |
| Beta | 2.23 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 3.78 | 200-d Avg | 6.44 | 1yr Est | 5.29 |
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backe
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-
On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restru
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins
Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade T
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and
Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweig
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to
Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outpe
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC,
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from
HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. T
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug
― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01
On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market.
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly los
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings